US FDA faces calls for clarity on confirmatory trials

The US Food and Drug Administration has received a range of responses to its draft guidance on the Accelerated Approval pathway, with industry groups and advocacy organizations raising concerns about post-approval study requirements.

While stakeholders broadly support the pathway’s goal of expediting access to treatments for serious conditions, some argue that certain aspects of the guidance require more clarity.

Clearer timelines needed